

# Xbrane Biopharma to participate at Redeye Growth Day 2020

**Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") represented by Martin Åmark, CEO, will participate at Redeye's Growth Day 2020.**

On June 2, at 5:30 PM, Martin Åmark, CEO, Xbrane Biopharma, will present the latest events and development in the Company at Redeye. The presentation will be live and can be followed at the below link,

<https://www.redeye.se/live/growth-day-2020>

Afterwards, the presentation will be available on Xbrane's company page at Redeye Universe:

<https://www.redeye.se/company/xbrane-biopharma>.

## Contacts

---

Martin Åmark, CEO/ IR  
M: +46 (0) 763-093 777  
E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Susanna Helgesen, CFO  
M: +46 (0) 708-278 636  
E: [susanna.helgesen@xbrane.com](mailto:susanna.helgesen@xbrane.com)

## About Us

---

*Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com).*

## Attachments

---

[Xbrane Biopharma to participate at Redeye Growth Day 2020](#)